Antiretroviral therapy and central nervous system HIV type 1 infection
about
Redefining the viral reservoirs that prevent HIV-1 eradicationRaltegravir cerebrospinal fluid concentrations in HIV-1 infectionHIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment.Review of functional MRI in HIV: effects of aging and medication.Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapyCerebral FDG-PET scanning abnormalities in optimally treated HIV patients.Neurocognitive development in HIV-positive children is correlated with plasma viral loads in early childhoodHIV protease inhibitor exposure predicts cerebral small vessel disease.Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transportPresentation and outcome of tuberculous meningitis in a high HIV prevalence setting.ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based studyHIV, dementia and antiretroviral drugs: 30 years of an epidemic.Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy.Polyamines: Predictive Biomarker for HIV-Associated Neurocognitive Disorders.Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapyLow levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settingsIncidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz.Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study.Molecular and pathologic insights from latent HIV-1 infection in the human brainMolecular epigenetics, chromatin, and NeuroAIDS/HIV: translational implications.Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.Neuropsychological assessment of HIV-infected populations in international settingsImplementing neuronal plasticity in NeuroAIDS: the experience of brain-derived neurotrophic factor and other neurotrophic factors.Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration?The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.The cannabinoid CB₂ receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis.Hearing Loss and Quality of Life (QOL) among Human Immunodeficiency Virus (HIV)-Infected and Uninfected AdultsSingle-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllersHIV reservoirs and the possibility of a cure for HIV infection.HIV-associated neurological disorders: a guide to pharmacotherapy.Interactions between prostaglandins, leukotrienes and HIV-1: possible implications for the central nervous system.'Time-to-amphotericin B' in cryptococcal meningitis in a European low-prevalence setting: analysis of diagnostic delays.Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy.
P2860
Q26827255-BF51CDF5-1F4A-4B76-B9C9-D682DA3C0F3EQ28476050-ADA2600C-4350-46CF-A9DA-A43BE0B97575Q30234305-BE79DB46-1064-4B70-8BAD-038CA04CE338Q31135624-32C22616-6BA7-4022-952A-205A3EB5A607Q33520347-62E2D824-30D1-4068-82AB-C215E071AF5CQ33552227-1465C4FE-D2D8-4F76-B55B-5167CF3BEC05Q33728851-1389B75B-76B8-470A-9216-E073FCA797D7Q33783344-67D2FCCC-B3E2-48BF-8E48-BDC506E73DF8Q33807507-D331FE30-BFBF-467E-9F0D-661E2031415AQ33870898-01A42E01-29B1-4EEC-AA84-E1A7033C9B9BQ33916426-162E96D5-79F5-4B36-A2CF-5F435C7F8F90Q34202181-2EE1088F-0CC5-4178-A67E-E605E27A96B3Q34455156-68EF99CA-94C8-408E-83B3-06E4DF7FDEA5Q34573511-22E97121-62D4-41AF-A140-8B5EB954B964Q34776835-3C35B0A9-5454-4CA7-8AB5-5982BE0A90FDQ34808562-F412B7A1-3CA3-417B-BCAB-1BC47F9F0FAFQ35424138-18973DEB-09C1-42AF-8DF1-8A03EA6EBFB9Q35532868-0945760F-4DED-4DEB-8DF2-148AD5AF0EF9Q35822465-D1391CBE-35AB-4BCF-8112-C73D9B1D3FB3Q35979166-741345B5-8EE2-4B75-9261-1E127038A94CQ35993860-54086130-CAC9-4534-A468-6F1A8BCE1EC4Q36062320-52A0F0A4-942C-4EB4-B345-20CE50DAEA53Q36379592-4A2F417F-8D83-420D-8697-41DAECEFD40BQ36869931-73A3AD41-1E32-42D8-AFAC-D4DF5A978DABQ36980773-A207C306-EE37-4144-A532-04872B9B4936Q37122279-EF463D0F-79B5-4392-8BB6-E57122EFF0E6Q37200979-FD5041FB-26CE-4B92-A79D-413D8153FE07Q37213350-BCA9EE1F-1362-43F7-B12E-CD270444D8BEQ37351271-A8E71D6A-EB9D-45B1-B793-949A114589DFQ37362071-3A180AEA-CC29-4DC9-8445-CDD22EC37A5BQ37379470-DD7C5CBF-228E-4AE9-A644-A3FAC87D773BQ37436136-1147F364-DDCC-4150-AB7B-B10A10240CAAQ37522883-61409413-4A73-458B-A10C-D0B4CB01A532Q37646944-A68C583C-CE7B-4276-AF54-AACC0B9E269FQ37732233-E1D4CE1F-6C32-465B-84FB-B111C94B0671Q37935109-3113DFCC-C68B-4630-BF36-6781CEEDFF48Q37971469-978733C4-47BC-48B8-8E0B-4F3A7B69ADBAQ37974980-49DA5118-8F79-4883-B170-B8BB32BA549BQ38203799-8BD866E2-E3CB-4E7F-B6A1-3B88CBF78345Q38414364-4DE77E00-7E8F-4C73-BCB5-DC3542AB27E1
P2860
Antiretroviral therapy and central nervous system HIV type 1 infection
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antiretroviral therapy and central nervous system HIV type 1 infection
@en
Antiretroviral therapy and central nervous system HIV type 1 infection.
@nl
type
label
Antiretroviral therapy and central nervous system HIV type 1 infection
@en
Antiretroviral therapy and central nervous system HIV type 1 infection.
@nl
prefLabel
Antiretroviral therapy and central nervous system HIV type 1 infection
@en
Antiretroviral therapy and central nervous system HIV type 1 infection.
@nl
P2860
P356
P1476
Antiretroviral therapy and central nervous system HIV type 1 infection
@en
P2093
Richard W Price
Serena Spudich
P2860
P304
P356
10.1086/533419
P407
P478
197 Suppl 3
P577
2008-05-01T00:00:00Z